Itami J, Ogata H, Shimizu K, Nemoto K, Yasuda S, Yoshida H, Mikata A, Arimizu N
Dept. of Radiology, School of Med., Chiba Univ.
Gan No Rinsho. 1990 Mar;36(4):499-504.
A M-BACOD regimen using an increased dose of Adriyamycin has been administered to 18 patients with non-Hodgkin's lymphoma. Sixty-three percent of the patients who had been previously untreated obtained a complete remission and the 2-year survival rate of those who evidenced a complete response reached 71%. The stage of the lymphoma was found to be a prognostic factor for a complete remission, while LDH and tumor response had an influence upon survival.
一种使用增加剂量阿霉素的M-BACOD方案已应用于18例非霍奇金淋巴瘤患者。63% 以前未接受过治疗的患者获得了完全缓解，而那些表现出完全缓解的患者的2年生存率达到了71%。发现淋巴瘤的分期是完全缓解的一个预后因素，而乳酸脱氢酶（LDH）和肿瘤反应对生存有影响。
